CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes

CML Stem Cell Burden at Diagnosis Associated With Treatment Outcomes By Dave Levitan March 11, 2013 Laboratory studies have suggested that chronic myeloid leukemia (CML) stem cells are resistant to tyrosine kinase inhibitor (TKI) treatment. A new study, though, showed for the first time the effect of stem cell burden on treatment outcome and actually found that TKIs, including imatinib(Drug information on imatinib) and dasatinib(Drug information on dasatinib), can rapidly eradicate most CML stem cells.